These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20652423)

  • 1. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).
    Krausz Y; Freedman N; Rubinstein R; Lavie E; Orevi M; Tshori S; Salmon A; Glaser B; Chisin R; Mishani E; J Gross D
    Mol Imaging Biol; 2011 Jun; 13(3):583-593. PubMed ID: 20652423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of [
    Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
    Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
    Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants.
    Kagna O; Pirmisashvili N; Tshori S; Freedman N; Israel O; Krausz Y
    AJR Am J Roentgenol; 2014 Dec; 203(6):1317-23. PubMed ID: 25415711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.
    Naswa N; Sharma P; Kumar A; Nazar AH; Kumar R; Chumber S; Bal C
    AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.
    Ambrosini V; Castellucci P; Rubello D; Nanni C; Musto A; Allegri V; Montini GC; Mattioli S; Grassetto G; Al-Nahhas A; Franchi R; Fanti S
    Nucl Med Commun; 2009 Apr; 30(4):281-6. PubMed ID: 19247211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
    J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.
    Prasad V; Ambrosini V; Hommann M; Hoersch D; Fanti S; Baum RP
    Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):67-77. PubMed ID: 19618183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
    Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.
    Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R
    Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.
    Ambrosini V; Nanni C; Zompatori M; Campana D; Tomassetti P; Castellucci P; Allegri V; Rubello D; Montini G; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):722-7. PubMed ID: 20107793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
    Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?
    Ambrosini V; Campana D; Nanni C; Cambioli S; Tomassetti P; Rubello D; Fanti S
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1278-83. PubMed ID: 22584487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
    Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of ⁶⁸Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study.
    Naswa N; Sharma P; Nazar AH; Agarwal KK; Kumar R; Ammini AC; Malhotra A; Bal C
    Eur Radiol; 2012 Mar; 22(3):710-9. PubMed ID: 21971823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.